• LAST PRICE
    0.3922
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.3910/ 25
  • Ask / Lots
    0.4950/ 25
  • Open / Previous Close
    0.0000 / 0.3922
  • Day Range
    ---
  • 52 Week Range
    Low 0.3200
    High 7.2300
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.42
TimeVolumeONPH
09:32 ET6000.42
09:42 ET1100.42
10:24 ET60000.4001
10:29 ET17940.405075
10:38 ET25000.405075
10:45 ET25000.401
10:49 ET32370.391
10:56 ET6570.391
11:02 ET162500.4
11:20 ET20000.39325
11:23 ET29000.391
11:25 ET10000.39775
11:36 ET15550.391
12:15 ET5000.39775
12:37 ET2000.391
12:53 ET1000.4
01:27 ET57130.4
02:09 ET3950.39825
02:23 ET1000.391
02:52 ET2000.391
02:56 ET30000.42
03:35 ET1650.41
03:55 ET10000.3922
03:57 ET1000.42
04:00 ET1000.3922
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesONPH
Oncology Pharma Inc
14.9M
0.0x
---
United StatesPCSA
Processa Pharmaceuticals Inc
13.9M
-0.8x
---
United StatesPYPD
PolyPid Ltd
16.7M
-0.3x
---
United StatesCLRB
Cellectar Biosciences Inc
17.8M
-0.4x
---
United StatesNDTP
NDT Pharmaceuticals Inc
11.8M
0.0x
---
United StatesLEXX
Lexaria Bioscience Corp
16.4M
-2.3x
---
As of 2023-02-08

Company Information

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Contact Information

Headquarters
1 Sansome St Ste 3500SAN FRANCISCO, CA, United States 94104-4436
Phone
415-869-1036
Fax
---

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.9M
Revenue (TTM)
$29.5K
Shares Outstanding
38.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.06
EPS
$-20,154,790.00
Book Value
---
P/E Ratio
0.0x
Price/Sales (TTM)
504.2
Price/Cash Flow (TTM)
---
Operating Margin
-75,237.89%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.